GlassScriptPhysician profile
Harry Macdannald
NPI 1306895313
$3,873.50
in general payments reported to CMS, 2019-2025
31 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $55.31 · 2021: $268 · 2022: $346 · 2023: $1,077 · 2024: $927 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.37 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $676.23 | 2022-2025 | |
| Inspire Medical Systems, INC. | $673.70 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $634.62 | 2019-2025 | Trelegy Ellipta, Nucala |
| Harmony Biosciences LLC | $297.37 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $201.97 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $175.26 | 2019-2024 | Breztri, Tezspire |
| Resmed Corp | $155.43 | 2021-2023 | |
| Axsome Therapeutics, INC. | $114.37 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.00 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $102.99 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $80.19 | 2021-2023 | Glassia |
| Dexcom, INC. | $75.17 | 2024-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $62.01 | 2024 | Hetlioz |
| Advanced Respiratory, INC | $57.45 | 2019-2020 | |
| Electromed, INC. | $52.11 | 2023-2024 | Smartvest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $41.95 | 2023-2025 | Arikayce |
| Pulmonx Corporation | $39.68 | 2021 | |
| Fresenius Kabi USA, LLC | $34.83 | 2025 | |
| Genentech USA, INC. | $34.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.33 | 2019 | |
| Merck Sharp & Dohme LLC | $32.97 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $31.19 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $29.08 | 2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $19.74 | 2025 | Recorlev |
| Fisher & Paykel Healthcare INC | $17.47 | 2022 | |
| Genzyme Corporation | $16.84 | 2024 | |
| Inogen, INC. | $16.38 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Lilly USA, LLC | $14.78 | 2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $14.71 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $13.36 | 2021 | |
| Zoll Respicardia, INC. | $13.21 | 2024 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Macdannald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.